Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells

NCT03070002 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped Low accrual

Conditions

Breast Carcinoma Metastatic in the Bone
Circulating Tumor Cell Count
Estrogen Receptor Positive
HER2/Neu Negative
Progesterone Receptor Positive
Stage IV Breast Cancer

Interventions

BIOLOGICAL: Denosumab
OTHER: Laboratory Biomarker Analysis

Sponsor

Northwestern University

Collaborators

[object Object]
[object Object]